Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. - Wikidata - wikimedia - TriplyDB

Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.

Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.

http://www.wikidata.org/entity/Q33711672

about

Lung microbiology and exacerbations in COPD Antibiotics for exacerbations of chronic obstructive pulmonary disease Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)Positioning new pharmacotherapies for COPD Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data.Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications.Lower airway colonization and inflammatory response in COPD: a focus on Haemophilus influenzae Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI)Genomic Investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen.A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease.Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial Clinical impact of chronic obstructive pulmonary disease on non-cystic fibrosis bronchiectasis. A study on 1,790 patients from the Spanish Bronchiectasis Historical Registry.Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease.Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial.Acute Exacerbation and Respiratory InfectionS in COPD (AERIS): protocol for a prospective, observational cohort study.The Saudi Guidelines for the Diagnosis and Management of COPD.Prophylactic antibiotic therapy in chronic obstructive pulmonary disease.The benefits of long-term systemic antimicrobial therapy in chronic obstructive pulmonary disease.The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis.What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease?COPD updates: what's new in pathophysiology and management?New anti-inflammatory targets for chronic obstructive pulmonary disease.Defining phenotypes in COPD: an aid to personalized healthcare.Pharmacotherapy for lower respiratory tract infections.An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations Prevention of infections in nursing homes: antibiotic prophylaxis versus infection control and antimicrobial stewardship measures.Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics?Nontypeable Haemophilus influenzae and chronic obstructive pulmonary disease: a review for clinicians.Treatment options for moderate-to-very severe chronic obstructive pulmonary disease.Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease.Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease.An update on the pharmacotherapeutic management of lower respiratory tract infections.Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.

P2860

Q22305860-01C741E0-4347-4117-B32C-86BA5DDC5CBF Q24202248-E0D3C1C7-5BE9-4766-AF11-DFBA57E330AC Q24202329-650F6FE3-EAC2-49BA-B58A-FE11A4C58CF3 Q26798659-B7284985-C9C4-4ACA-9D31-58347CB0DD42 Q28071694-66E46D5D-2250-4197-AA56-FBF8837FBF10 Q30949429-79692EEC-4614-46B3-B959-998F8332432E Q34039712-312327FB-574B-46F8-A8B8-F95AEA54369B Q34386841-43EFD3BC-C3D1-4A64-88B8-CCDDB12F04EB Q34550471-AE6B2DDB-957D-4143-BD6B-B1DDB5889E62 Q34560033-D5DFF241-9AF7-45C1-A023-C609D754247B Q34946001-AB9287EA-EFB0-417F-A9AE-C9278D473BC7 Q36035081-2A136719-4C71-4426-BBC9-5DA1A75F3CE7 Q36093531-BF0AB32D-FCE4-4A73-8DF8-F8F36098DBD7 Q36150134-F04C0A08-9B58-4D2F-8D7A-9951EE68DA60 Q36380278-049507D1-A2B7-49E3-81A5-09459108F618 Q36526951-73F54EE0-FBB6-4DC1-BC14-8588078B31DB Q37023332-79849529-7FE3-4801-B617-409A07AFAE06 Q37177278-28F71B70-0DD8-4CE4-8E42-6574C5D9BBDE Q37582484-0869F1BF-4EA3-44DF-9BDC-DBEC517A6BEA Q37628494-C05613D7-76F5-4200-B5AF-BD135DDE78D4 Q37733309-777E3FD6-2702-428A-BD4B-63D0F98FBA73 Q37763372-A0C79D78-3B15-446E-AEEA-6D549A91C472 Q37850201-FE40625C-26F6-4088-99F4-634A01D28D24 Q38056764-67F1EE97-F808-4129-AC66-813EEB88A63E Q38095562-A15B64C0-CD30-4E80-ADC4-FD36A8A17621 Q38130515-3A603EA9-9C84-4339-8502-605023E180A7 Q38131512-0C4E28ED-F652-45E5-B4FD-2BE58EE9F3A8 Q38208244-77813DF9-6CAD-47AF-800F-E097A9EB962A Q38248719-45EAD41A-6166-41CC-A83D-A7639BEE65EF Q38399184-65993094-7DA6-4C5C-BB95-DF0854A22CB5 Q38624850-465E932D-6FBA-4ABF-84DE-7E78A5704AA1 Q38665838-8DF18FB7-C1C8-450E-B6B0-2DB6A4A4986C Q38667550-D38F9CE4-0F63-4D94-B22A-6980C94621B2 Q38679715-2705E303-D9AD-4E07-9058-6F5D3DDADA12 Q38740756-1AB11EB9-5951-4872-BEEB-152F803B9B8C Q39370816-A502C05D-83E7-4E27-8A07-0AF6A9887FFF Q40106829-4B5B07E7-8EF7-4D1B-A245-A0632BB1DE80 Q40222424-9C67C1E7-82CD-4B08-958F-51067E8726F0 Q41071899-261DFA8B-701F-4F5A-9DC6-20CF374BE8B2 Q41400495-9484FD20-0B83-450C-BCC9-CB9AB4888FA2

P2860

Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.

http://www.wikidata.org/entity/Q33711672

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Pulsed moxifloxacin for the pr ...... a randomized controlled trial.

@ast

Pulsed moxifloxacin for the pr ...... a randomized controlled trial.

@en

type

label

Pulsed moxifloxacin for the pr ...... a randomized controlled trial.

@ast

Pulsed moxifloxacin for the pr ...... a randomized controlled trial.

@en

prefLabel

Pulsed moxifloxacin for the pr ...... a randomized controlled trial.

@ast

Pulsed moxifloxacin for the pr ...... a randomized controlled trial.

@en

P1433

Q33711672-BF88A13F-F9E1-4B0E-B352-CB1309F01909

P1476

Q33711672-5B77E2CE-3F6D-41F9-A6BC-857E72A97BCE

P2093

Q33711672-286913B1-EBD2-4BB9-93B3-D34F1CEB3ECC

Q33711672-62DA1048-143C-4CB9-A3FD-7424A8680B47

Q33711672-AD2FE518-A75B-4465-9444-753F742419F5

Q33711672-B6D222C0-FF2A-4664-95D6-5819F7149816

Q33711672-B7318178-BB26-43B5-882F-23ED6165790B

Q33711672-C0886A0B-13CE-4BB8-AD50-FD481259CFA8

Q33711672-EF29767F-BD68-4B73-91E2-DA4D2222E46D

P2860

Q33711672-0422EECA-02C2-4C5E-A2C0-910432BC40CC

Q33711672-0B4B14DE-7D58-4ACF-BC26-FE527613F665

Q33711672-0EBFF0A3-6412-4547-8218-B4B1E2CECAF2

Q33711672-2A5D1DAD-0300-4656-9A04-CA20228C2685

Q33711672-3580BA36-85ED-494C-B9FE-576FF3FE6CC4

Q33711672-371A5600-6D3D-47EE-9CFA-723D58A019B2

Q33711672-40261EB9-4FAE-47CE-A818-ED2BBC695A13

Q33711672-47E3377C-D92B-4495-AD94-FA0B007FEE6C

Q33711672-4E8C0B87-4C28-4335-A6FE-E4526D3E74EF

Q33711672-60322036-4411-4C4A-AADA-E7D8C0AFF68F

P2888

Q33711672-5EF3E105-4185-426F-82B2-84A3EDC107A7

P304

Q33711672-9A09A6DE-A804-4C72-AA5D-BBAAA50D7812

P31

Q33711672-A2DFAC1D-043B-4E75-AB64-CD10B1516364

P356

Q33711672-D2715AAB-E98C-4D97-BF10-E2317E3DA764

P478

Q33711672-617920F5-7BBF-42E7-A015-A5E96F7A16F5

P50

Q33711672-F5F99E97-64E5-4BAD-A41C-9EB853BD5919

P577

Q33711672-E3D029F4-0F45-4F62-82F9-D45F3E2AEB38

P5875

Q33711672-71D22D97-B6BB-4BBF-B774-339EE1B7E39A

P6179

Q33711672-93693911-20D2-424C-B9BC-C4499FFF1B17

P698

Q33711672-E3630B28-6BDC-48C4-B02D-B17BA05B6078

P921

Q33711672-DFA094EF-3A55-4733-A63A-87981E33347E

P932

Q33711672-F17C6B3C-3174-4724-9ED5-DD696A16475E

P356

1465-9921-11-10

P1433

Respiratory Research

P1476

Pulsed moxifloxacin for the pr ...... a randomized controlled trial.

@en

P2093

Ethan Rubinstein

http://www.w3.org/2001/XMLSchema#string

Jadwiga A Wedzicha

http://www.w3.org/2001/XMLSchema#string

Marlize Schmitt Theron

http://www.w3.org/2001/XMLSchema#string

PULSE Study group

http://www.w3.org/2001/XMLSchema#string

Paul W Jones

http://www.w3.org/2001/XMLSchema#string

Robert Wilson

http://www.w3.org/2001/XMLSchema#string

Sanjay Sethi

http://www.w3.org/2001/XMLSchema#string

P2860

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.

Prophylactic antibiotic therapy for chronic bronchitis.

Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease.

Infection and COPD.

Patient adherence in COPD.

P2888

1465-9921-11-10

P304

10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1465-9921-11-10

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Marc Miravitlles

P577

2010-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41172534

http://www.w3.org/2001/XMLSchema#string

P6179

1030971985

http://www.w3.org/2001/XMLSchema#string

P698

20109213

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

P932

2834642

http://www.w3.org/2001/XMLSchema#string